| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1078-0432.CCR-11-1625 |
| P698 | PubMed publication ID | 22128302 |
| P2093 | author name string | Yi Yang | |
| Mary L Disis | |||
| Margaret Inokuma | |||
| Vernon C Maino | |||
| Hailing Lu | |||
| Robert M Hershberg | |||
| Gregory N Dietsch | |||
| Maria Suni | |||
| Smita Ghanekar | |||
| Katherine E Henderson | |||
| Maura-Ann H Matthews | |||
| James Jeffry Howbert | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | toll-like receptor | Q408004 |
| P304 | page(s) | 499-509 | |
| P577 | publication date | 2011-11-29 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC. | |
| P478 | volume | 18 |
| Q41000160 | A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells |
| Q33608191 | A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study. |
| Q90594140 | Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes |
| Q54385315 | Cancer Vaccines in Ovarian Cancer: How Can We Improve? |
| Q55005404 | Cetuximab combined with natural killer cells therapy: an alternative to chemoradiotherapy for patients with advanced non-small cell lung cancer (NSCLC). |
| Q41886564 | Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer. |
| Q38014085 | Combination strategies to enhance antitumor ADCC. |
| Q64881207 | Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity. |
| Q35940189 | Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity |
| Q59477539 | Costimulatory and coinhibitory immune checkpoint receptors in head and neck cancer: unleashing immune responses through therapeutic combinations |
| Q92965276 | Discovery of HSPG2 (Perlecan) as a Therapeutic Target in Triple Negative Breast Cancer |
| Q40089704 | EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise. |
| Q38240998 | Early investigational drugs that target epidermal growth factor receptors for the treatment of head and neck cancer |
| Q88549071 | Emerging Systemic Therapies for Colorectal Cancer |
| Q38563897 | Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30. |
| Q42096062 | Exquisite selectivity for human toll-like receptor 8 in substituted furo[2,3-c]quinolines. |
| Q38301125 | Granzyme B expression is enhanced in human monocytes by TLR8 agonists and contributes to antibody-dependent cellular cytotoxicity |
| Q37309932 | Human TLR8 is activated upon recognition of Borrelia burgdorferi RNA in the phagosome of human monocytes |
| Q34164851 | Human Toll-like receptor 8-selective agonistic activities in 1-alkyl-1H-benzimidazol-2-amines |
| Q92661192 | Identification of CNS Injury-Related microRNAs as Novel Toll-Like Receptor 7/8 Signaling Activators by Small RNA Sequencing |
| Q97553625 | Immune Sensing Mechanisms that Discriminate Self from Altered Self and Foreign Nucleic Acids |
| Q58553701 | In vivo cancer vaccination: Which dendritic cells to target and how? |
| Q38240851 | Insights into the Relationship between Toll Like Receptors and Gamma Delta T Cell Responses |
| Q38162129 | Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer |
| Q30275792 | Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy |
| Q47156322 | Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy. |
| Q38193822 | Monocyte/macrophage inflammatory response pathways to combat Francisella infection: possible therapeutic targets? |
| Q42177189 | Motolimod effectively drives immune activation in advanced cancer patients |
| Q52722200 | Mycobacterium tuberculosis Transfer RNA Induces IL-12p70 via Synergistic Activation of Pattern Recognition Receptors within a Cell Network. |
| Q28071998 | Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma |
| Q90411193 | Novel immune-modulating drugs for advanced head and neck cancer |
| Q38661106 | Novel targets for natural killer/T-cell lymphoma immunotherapy |
| Q90288795 | Pharmacological modulation of nucleic acid sensors - therapeutic potential and persisting obstacles |
| Q47735681 | Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals |
| Q38305650 | Potential approaches for more successful dendritic cell-based immunotherapy |
| Q26738443 | Radiotherapy combination opportunities leveraging immunity for the next oncology practice |
| Q93204275 | Recent clinical trends in Toll-like receptor targeting therapeutics |
| Q28246233 | Role of toll-like receptors in cervical, endometrial and ovarian cancers: a review |
| Q38039958 | Roles of toll-like receptors in cancer: a double-edged sword for defense and offense |
| Q38841677 | Strategies for designing synthetic immune agonists |
| Q27681499 | Structure-Based Design of Novel Human Toll-like Receptor 8 Agonists |
| Q41997055 | TLR Agonists as Adjuvants for Cancer Vaccines. |
| Q38173691 | TLR-mediated activation of NK cells and their role in bacterial/viral immune responses in mammals |
| Q93221565 | TLR8 and its endogenous ligand miR-21 contribute to neuropathic pain in murine DRG |
| Q49977478 | TLR8 ligation induces apoptosis of monocytic myeloid-derived suppressor cells. |
| Q39150078 | TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells |
| Q27026056 | TLR8: the forgotten relative revindicated |
| Q26783195 | Targeted Therapies in Adult B-Cell Malignancies |
| Q102210856 | Targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies |
| Q35159974 | The expression of Toll-like receptor 8 and its relationship with VEGF and Bcl-2 in cervical cancer. |
| Q35288072 | The role of TLR8 signaling in acute myeloid leukemia differentiation |
| Q34618662 | The ultra-potent and selective TLR8 agonist VTX-294 activates human newborn and adult leukocytes. |
| Q39090441 | The use of nanolipoprotein particles to enhance the immunostimulatory properties of innate immune agonists against lethal influenza challenge |
| Q49736961 | Toll-Like Receptor 8 Agonist Strengthens the Protective Efficacy of ESAT-6 Immunization to Mycobacterium tuberculosis Infection |
| Q89587299 | Toll-Like Receptors Signaling in the Tumor Microenvironment |
| Q93080297 | Toll-Like Receptors and Relevant Emerging Therapeutics with Reference to Delivery Methods |
| Q94596489 | Toll-Like Receptors in Natural Killer Cells and Their Application for Immunotherapy |
| Q26861234 | Toll-like Receptors in Ovarian Cancer as Targets for Immunotherapies |
| Q36884862 | Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma |
| Q36194849 | Trial Watch: Experimental Toll-like receptor agonists for cancer therapy |
| Q28067939 | Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy |
| Q42969291 | Trial Watch: Toll-like receptor agonists for cancer therapy |
| Q30387055 | VTX-1463, a novel TLR-8 agonist, attenuates nasal congestion after ragweed challenge in sensitized beagle dogs. |
| Q92726625 | p53-responsive TLR8 SNP enhances human innate immune response to respiratory syncytial virus |
Search more.